Pifoxime
Pifoxime is an oxime derivative with cholinesterase reactivating properties that was investigated as a treatment for organophosphate poisoning by regenerating inhibited acetylcholinesterase at neuromuscular junctions and in the central nervous system. Its clinical development was limited relative to pralidoxime, which became the standard oxime reactivator in organophosphate toxicity management.
Moleküler Ağırlık
276,3300 g/mol
LogP
1,80
TPSA
62,10 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
C/C(=N\O)c1ccc(OCC(=O)N2CCCCC2)cc1
InChI
InChI=1S/C15H20N2O3/c1-12(16-19)13-5-7-14(8-6-13)20-11-15(18)17-9-3-2-4-10-17/h5-8,19H,2-4,9-11H2,1H3/b16-12+
Molecular Formula
C15H20N2O3
HBD / HBA
1 / 4
Döndürülebilir Bağlar
4
Ağır Atomlar
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Pifoxime is an oxime derivative with cholinesterase reactivating properties that was investigated as a treatment for organophosphate poisoning by regenerating inhibited acetylcholinesterase at neuromuscular junctions and in the central nervous system. Its clinical development was limited relative to pralidoxime, which became the standard oxime reactivator in organophosphate toxicity management.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Pifoxime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1998966. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 35755. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pifoxime"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pifoxime/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pifoxime/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pifoxime/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pifoxime"></drugfyi-drug>